Neumora Q2 FY26 net loss narrows to $43.1 million

Reuters2026/08/14 11:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Neumora posted a GAAP net loss of USD 43.1 million, narrowing from USD 52.7 million a year earlier.
R&D expense fell 24.33% to USD 29.3 million, due to lower clinical trial costs and reduced personnel-related costs.
G&A expense dropped 15.77% to USD 12.9 million on lower personnel-related costs.
Cash and cash equivalents totaled USD 116.8 million at June 30, expected to fund operations into Q3 2027.
Pipeline milestones include NMRA-215 IND planned for Q4 2026, NMRA-511 data expected Q4 2026, NMRA-898 data due in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140700PRIMZONEFULLFEED9810046) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Neumora Q2 FY26 net loss narrows to $43.1 million

You may also like

Crypto prices